Global Anti-Obesity Drugs (Anti-obesity Medication) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories.
Anti-Obesity Drugs (Anti-obesity Medication) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-Obesity Drugs (Anti-obesity Medication) market is projected to reach US$ 5569.5 million in 2034, increasing from US$ 1824.1 million in 2022, with the CAGR of 17.0% during the period of 2024 to 2034. Demand from Childhood (0-6) and Juvenile (7-17) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-Obesity Drugs (Anti-obesity Medication) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Anti-Obesity Drugs (Anti-obesity Medication) key manufacturers include Zafgan, Vivus, Shionogi, Sanofi, Rhythm Pharmaceuticals, Pfizer, Orexigen Therapeutics, Novo Nordisk and Norgine, etc. Zafgan, Vivus, Shionogi are top 3 players and held % sales share in total in 2022.
Anti-Obesity Drugs (Anti-obesity Medication) can be divided into Prescription Drugs and OTC Drugs, etc. Prescription Drugs is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-Obesity Drugs (Anti-obesity Medication) is widely used in various fields, such as Childhood (0-6), Juvenile (7-17), Youth (18-40) and Middle Aged (41-60), etc. Childhood (0-6) provides greatest supports to the Anti-Obesity Drugs (Anti-obesity Medication) industry development. In 2022, global % sales of Anti-Obesity Drugs (Anti-obesity Medication) went into Childhood (0-6) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-Obesity Drugs (Anti-obesity Medication) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Zafgan
Vivus
Shionogi
Sanofi
Rhythm Pharmaceuticals
Pfizer
Orexigen Therapeutics
Novo Nordisk
Norgine
Nalpropion Pharmaceuticals Inc.
Merck
GlaxoSmithKline
F.Hoffmann-La Roche
Eisai
Boehringer Ingelheim
Bayer AG
AstraZeneca
Arena Pharmaceuticals
Amylin
Alizyme
Segment by Type
by Drug Varieties
Prescription Drugs
OTC Drugs
by Acting
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Childhood (0-6)
Juvenile (7-17)
Youth (18-40)
Middle Aged (41-60)
Elderly (Above 60)
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-Obesity Drugs (Anti-obesity Medication) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-Obesity Drugs (Anti-obesity Medication), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-Obesity Drugs (Anti-obesity Medication) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-Obesity Drugs (Anti-obesity Medication) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-Obesity Drugs (Anti-obesity Medication) introduction, etc. Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Anti-Obesity Drugs (Anti-obesity Medication) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Anti-Obesity Drugs (Anti-obesity Medication) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-Obesity Drugs (Anti-obesity Medication) market is projected to reach US$ 5569.5 million in 2034, increasing from US$ 1824.1 million in 2022, with the CAGR of 17.0% during the period of 2024 to 2034. Demand from Childhood (0-6) and Juvenile (7-17) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-Obesity Drugs (Anti-obesity Medication) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Anti-Obesity Drugs (Anti-obesity Medication) key manufacturers include Zafgan, Vivus, Shionogi, Sanofi, Rhythm Pharmaceuticals, Pfizer, Orexigen Therapeutics, Novo Nordisk and Norgine, etc. Zafgan, Vivus, Shionogi are top 3 players and held % sales share in total in 2022.
Anti-Obesity Drugs (Anti-obesity Medication) can be divided into Prescription Drugs and OTC Drugs, etc. Prescription Drugs is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-Obesity Drugs (Anti-obesity Medication) is widely used in various fields, such as Childhood (0-6), Juvenile (7-17), Youth (18-40) and Middle Aged (41-60), etc. Childhood (0-6) provides greatest supports to the Anti-Obesity Drugs (Anti-obesity Medication) industry development. In 2022, global % sales of Anti-Obesity Drugs (Anti-obesity Medication) went into Childhood (0-6) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-Obesity Drugs (Anti-obesity Medication) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Zafgan
Vivus
Shionogi
Sanofi
Rhythm Pharmaceuticals
Pfizer
Orexigen Therapeutics
Novo Nordisk
Norgine
Nalpropion Pharmaceuticals Inc.
Merck
GlaxoSmithKline
F.Hoffmann-La Roche
Eisai
Boehringer Ingelheim
Bayer AG
AstraZeneca
Arena Pharmaceuticals
Amylin
Alizyme
Segment by Type
by Drug Varieties
Prescription Drugs
OTC Drugs
by Acting
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Segment by Application
Childhood (0-6)
Juvenile (7-17)
Youth (18-40)
Middle Aged (41-60)
Elderly (Above 60)
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-Obesity Drugs (Anti-obesity Medication) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-Obesity Drugs (Anti-obesity Medication), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-Obesity Drugs (Anti-obesity Medication) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-Obesity Drugs (Anti-obesity Medication) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-Obesity Drugs (Anti-obesity Medication) introduction, etc. Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Anti-Obesity Drugs (Anti-obesity Medication) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices